Oncternal Therapeutics, Inc. (ONCT) announced the discontinuation of its clinical trials ONCT-534 and ONCT-808 on Thursday, alongside plans to consider strategic alternatives. following the news the shares are down 58%. ONCT-534 is a dual-action androgen receptor inhibitor aimed at treating metastatic castration-resistant cancer, while ONCT-808 is an autologous CAR T therapy targeting ROR1 in aggressive B-cell lymphoma.The decision comes after interim Phase 1 results for ONCT-534 showed no significant improvements in a group of 20 patients across eight dosing levels.

Oncentral Therapeutics，Inc.（ONCT）周四宣布停止其ONCT-534和ONCT-808临床试验，并计划考虑战略替代方案。消息传出后，股价下跌了58%。ONCT-534是一种双重作用的雄激素受体抑制剂，旨在治疗转移性去势抵抗性癌症，而ONCT-808是一种针对侵袭性B细胞淋巴瘤中ROR1的自体CAR T疗法。这一决定是在ONCT-534的中期第一阶段结果显示，在8个剂量水平的20名患者中，没有显着改善之后做出的。

Although ONCT-808 demonstrated certain anti-tumor effects, it raised safety concerns due to a death linked to complications. .

尽管ONCT-808表现出一定的抗肿瘤作用，但由于与并发症相关的死亡，它引起了安全问题。

The company stated that it would shift its focus toward maximizing shareholder value through potential asset sales, licensing agreements, or business combinations. Furthermore, during this transition, all product development will be halted, and workforce reductions will take place to conserve cash resources.Currently, ONCT's stock is trading at $1.70, down 58.02% on the Nasdaq.

该公司表示，将通过潜在的资产销售、许可协议或企业合并，将重点转向股东价值最大化。此外，在此过渡期间，所有产品开发都将停止，并将减少劳动力以节省现金资源。目前，ONCT的股价为1.70美元，在纳斯达克下跌58.02%。

For comments and feedback contact: editorial@rttnews.comBusiness News.

如需评论和反馈，请联系：editorial@rttnews.comBusiness新闻。

Get Access to Premium Stock Alerts with RTT Intelligent Investor.

使用RTT Intelligent Investor访问溢价股票警报。

Biotech Stocks Facing FDA Decision In August 2024

2024年8月美国食品和药物管理局（FDA）决定生物技术股

Biotech Stocks Facing FDA Decision In June 2024

2024年6月美国食品和药物管理局（FDA）决定生物技术股

Biotech Stocks Facing FDA Decision In April 2024

2024年4月美国食品和药物管理局（FDA）决定生物技术股